Catastrophic expenditure and impoverishment of patients affected by 7 rare diseases in China

Orphanet Journal of Rare Diseases

Volumn 11, Issue 1, 2016, Pages

  Xin, Xiao Xiong ^a   Guan, Xiao Dong ^a,b   Shi, Lu Wen ^a,b  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b PEKING UNIVERSITY   (China)

Author keywords

Affordability; Catastrophic expenditure; Impoverishment effect; Orphan drug; Rare disease

Indexed keywords

ORPHAN DRUG;

ALPORT SYNDROME; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; CHINA; DRUG COST; DRUG USE; DUCHENNE MUSCULAR DYSTROPHY; FIBROSING ALVEOLITIS; FINANCIAL MANAGEMENT; GAUCHER DISEASE; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH INSURANCE; HUMAN; POVERTY; PULMONARY HYPERTENSION; RARE DISEASE; RURAL POPULATION; SOCIAL SECURITY; SOCIAL STATUS; TUBEROUS SCLEROSIS; TUBEROUS SCLEROSIS COMPLEX; URBAN POPULATION; DRUG MANUFACTURE; ECONOMICS; RARE DISEASES; STATISTICS AND NUMERICAL DATA;

CHINA; HEALTH EXPENDITURES; HUMANS; ORPHAN DRUG PRODUCTION; RARE DISEASES;

EID: 84975789846     PISSN: None     EISSN: 17501172     Source Type: Journal    
DOI: 10.1186/s13023-016-0454-7     Document Type: Article

References (26)

1. Liu X, Cui YZ, Li Y, Wang C, Zhao H, Han JX. Using inpatient data to estimate the prevalence of Wegener's granulomatosis in China. Intractable Rare Dis Res. 2016;5(1):31-5. doi: 10.5582/irdr.2015.01015.
2. Gong SW, Jin S. Current progress in the management of rare diseases and orphan drugs in China. Intractable Rare Dis Res. 2012;1(2):45-52. doi: 10.5582/irdr.2012.v1.2.45.
3. Tao Y, Shao YF, Zhang C, Guo C, Lei L. The Past and Present of Orphan Drug Management System in US. Chin Pharm J. 2001;9:58-60. doi: 10.3321/j.issn:1001-2494.2001.09.023.
4. Liu YC, Dong JP. Studies on Management Status of Rare Diseases and Orphan Drug in European Union. Chin Pharm J. 2012;47(5):395-8.
5. Gong SW. Study of Management Strategies of Improving Access to Orphan Drugs in China. Hubei: Huazhong University of Science and Technology, 2008. doi: 10.7666/d.d066054.
6. Song PP, Gao JJ, Inagaki Y, Kokudo N, Tang W. Intractable and rare diseases research in Asia. Biosci Trends. 2012;6(2):48-51. doi: 10.5582/bst.2012.v6.2.48.
7. Cameron A, Ewen M, Ross-Degnan D, et al. Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis. Lancet. 2008;373:240-9. doi: 10.1016/S0140-6736(08)61762-6.
8. Xu K, Evans DB, Kawabata K, et al. Household catastrophic health expenditure: a multicountry analysis. Lancet. 2003;362:111-7. doi: 10.1016/S0140-6736(03)13861-5.
9. Wagstaff A, Van Doorslaer E. Catastrophe and impoverishment in paying for health care: with applications to Vietnam 1993-98. Health Econ. 2003;12:921-34. doi: 10.1002/hec.776.
10. Rare Diseases Search. Paris: Orphanet 2015. (http://www.orpha.net/consor/cgi-bin/Disease.php?lng=EN) Accessed 20 Nov 2015.
11. Designing Health Financing Systems to Reduce Catastrophic Health Expenditure. Geneva: World Health Organization, 2015. (http://apps.who.int/iris/bitstream/10665/70005/1/WHO-EIP-HSF-PB-05.02-eng.pdf) Accessed 12 Oct 2015.
12. 2015 Chinese Statistical Yearbook. Beijing: National Bureau of Statistics of China, 2015. (http://www.stats.gov.cn/tjsj/ndsj/2015/indexch.htm) Accessed 2 Dec 2015.
13. Guan XD. Research on National Essential Medicine Policy Evaluation in China. Beijing: Peking University; 2011.
14. 2014 Statistical Bulletin of Social Service Development. Beijing: Ministry of Civil Affairs of the People's Republic of China. (http://www.mca.gov.cn/article/sj/tjgb/201506/201506008324399.shtml) Accessed 2 Dec 2015.
15. Simoens S. Pricing and reimbursement of orphan drugs: the need for more transparency. Orphanet J Rare Dis. 2011;6:42. doi: 10.1186/1750-1172-6-42.
16. Arhin-Tenkorong D. Mobilizing resource for health: the case for user fees revisited. (http://www.cid.harvard.edu/cidwp/pdf/081.pdf) Accessed 16 Sept 2015.
17. Bidani B, Ravallion M. Decomposing social indicators using distributional data. J Econ. 1997;77:125-39. doi: 10.1016/S0304-4076(95)01809-3.
18. Wagstaff A. Poverty and health sector inequalities. Bull World Health Organ. 2002;80:97-105.
19. Gansu government. Gansu Health and Family Planning Commission reported the epidemiological investigation results of five chronic epidemic diseases. (http://www.gansu.gov.cn/art/2014/8/19/art-36-193018.html) Accessed 5 Dec 2015.
20. Feng J, Xia ZG. Analysis of trends in cases of malaria reported form 2004 to July 2013 in People's Republic of China. J Pathog Biol. 2014;5:442-6.
21. Creese A, Kuznets J. Lessons from cost recovery in health: forum on health sector reform. WHO/SHS/NHP/95.5. Geneva: World Health Organization; 1997.
22. Gilson L. The lessons of user fee experience in Afirca. Health Policy Plan. 1997;12:273-85. doi: 10.1093/oxfordjournals.heapol.a018882.
23. Gong SW, Wang YX, Pan XY, et al. The availability and affordability of orphan drugs for rare diseases in China. Orphanet J Rare Dis. 2016;11:20. doi: 10.1186/s13023-016-0392-4.
24. Choosing Interventions that are Cost Effective (WHOCHOICE), Threshold values for intervention cost-effectiveness by Region. Geneva: World Health Organization, 2015. (http://www.who.int/entity/choice/costs/CER-thresholds-regions.xls) Accessed 25 Sept 2015.
25. Niëns LM, Van de Poel E, Cameron A, et al. Practical measurement of affordability: an application to medicines. Bull World Health Organ. 2012;90(3):219-27. doi: 10.2471/BLT.10.084087.
26. Gao JJ, Song PP, Tang W. Rare disease patients in China anticipate the sunlight of legislation. Drug Discov Ther. 2013;7(3):126-8. doi: 10.5582/ddt.2013.v7.3.126.